We have just released the latest update to the Open Targets Platform — 23.12.
Key highlights for this release:
This release integrates 16,710,896 evidence strings to build 7,994,180 target-disease associations between 25,246 diseases and 62,733 targets from the following 23 public resources:
- 2,907,730 genetic evidence from European Variation Archive (EVA)
- 781,800 genetic evidence from Open Targets Genetics
- 3,006 genetic evidence from Gene2Phenotype
- 31,420 genetic evidence from the Genomics England PanelApp
- 2,261 genetic evidence from ClinGen
- 6,355 genetic evidence from Orphanet
- 27,381 genetic evidence from Gene burden
- 24,886 genetic evidence from CRISPRBrain
- 4,130 genetic evidence from UniProt Literature
- 17,154 somatic evidence from European Variation Archive (EVA)
- 4,359 somatic evidence from intOGen
- 76,289 somatic evidence from the Cancer Gene Census
- 26,212 somatic evidence from Uniprot
- 624,960 drug evidence from ChEMBL
- 230,893 expression evidence from Expression Atlas
- 10,100 affected pathway evidence from Reactome
- 72,440 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,300 somatic evidence from the Cancer Genome Interpreter
- 1,838 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,033,889 mouse model evidence from IMPC
- 10,821,726 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 17,095 drugs.
For more details, read the 23.12 blog post.
Let us know what you think of the new features by commenting below!